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Introduction: Oxalate nephropathy has various etiologies and remains a rare cause of renal failure. To the best of
our knowledge, we report the first case of oxalate nephropathy following octreotide therapy.
Case presentation: We report the case of a 78-year-old Caucasian man taking chronic octreotide treatment for
acromegaly who presented with acute oxalate nephropathy after antibiotic therapy. The diagnosis was confirmed
by urinary analysis and a kidney biopsy. The recovery of renal function was favorable after hydration and
withdrawal of octreotide therapy.
Conclusions: Oxalate nephropathy should be suspected in patients at risk who present with acute kidney injury
after prolonged antibiotic treatment. This diagnosis should be distinguished from immuno-allergic interstitial
nephritis and requires specific care. The evolution of this condition may be favorable if the pathology is identified
correctly. Octreotide therapy should be considered a risk factor for enteric oxaluria.
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Oxalate nephropathy is characterized by tubular depos-
ition of calcium oxalate crystals due to either abnormal
oxalate production or excretion. This condition can lead
to acute and chronic tubular injury, interstitial fibrosis
and progressive renal insufficiency. The etiologies of ox-
alate nephropathy are divided into primary and second-
ary hyperoxaluria. Primary hyperoxaluria is a rare
autosomal recessive inherited metabolic disorder which
leads to an increase in endogenous oxalate synthesis
resulting in increased urinary oxalate excretion. Second-
ary hyperoxaluria is due to increased intestinal oxalate
absorption, excessive dietary oxalate intake or excessive
intake of oxalate precursors. Enteric hyperoxaluria due
to malabsorption is principally caused by inflammatory
bowel disease, jejuno-ileal bypass, short bowel syndrome,
pancreatic insufficiency or alteration of oxalate degrad-
ing bacteria. More rarely, genetic alterations of intestinal
oxalate transporters may be incriminated. Calcium plays
a major role in the normal intestinal elimination of oxal-
ate since it binds to oxalate in the intestinal lumen,* Correspondence: Karim.Gariani@hcuge.ch
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reproduction in any medium, provided the orthereby impeding its absorption. Malabsorption syn-
dromes lead to increased oxalate absorption via two
mechanisms: excessive non-absorbed fatty acid will che-
late free calcium, resulting in increased free oxalate that
will be reabsorbed and excreted by the kidney; in
addition, fatty acids and dihydroxyl bile acids cause an
increase in the permeability of the intestinal mucosa to
oxalate also contributing to hyperoxaluria. This excess of
oxalate urinary excretion may lead to either acute or
chronic oxalate nephropathy.
We report a case of acute oxalate nephropathy asso-
ciated with tubulointerstitial fibrosis in a patient treated
for acromegaly with octreotide.
Case presentation
A 78-year-old Caucasian man was admitted because of
acute kidney injury to our hospital. His medical history
was remarkable for acromegaly diagnosed 25 years ago
that was first treated with radiotherapy. Due to a re-
sidual secretion of growth hormone he was then treated
with octreotide for 10 years (10 mg every six weeks) with
an adequate control of his insulin-like growth factor −1
(IGF-1) level. His medical history also revealed weight
loss of 15 kg in the last four months without fever, dys-
uria, diarrhea or other symptoms.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sulfamethoxazole-trimethoprim and ciprofloxacin for a
urinary tract infection. This treatment was followed by a
partially regressive acute kidney injury that was attribu-
ted to immuno-allergic nephritis. No further investiga-
tions were undertaken at that time. His residual renal
function was estimated to be 50 ml/minute/1.73 m2
according to the MRDR4 system.
During the weeks preceding admission a urinary culture
yielded a multiresistant Enterobacteria which resulted in
multiple successive antibiotic treatments (penicillin and
two cephalosporins) over a period of five weeks. A rise in
creatinine level was noted following these treatments. He
was hospitalized for investigation of an acute kidney injury.
Upon hospital admission he was afebrile. His blood
pressure was 120/70 mmHg and pulse rate was 72 per
minute. His physical examination was unremarkable and
there was no skin rash or lymphadenopathy
Laboratory studies were notable for a creatinine level
of 4.9 mg/dL with conserved diuresis, resulting in stage
F acute kidney injury according to the RIFLE (risk, in-
jury, failure, loss, and end stage kidney disease (>three
months))classification, a HCO3 level of 18.9 mM (22 to
29 mM), a phosphorus level of 6.59 mg/dL (normal 2.5
to 8.5 mg/dL) and a calcium level of 8.8 mg/dL (normal
8.5 to 10.5 mg/dL). He also had mild anemia. His
leukocyte count was normal without eosinophilia. Urine
dipstick showed traces of protein and hemoglobin. Im-
munologic tests were unremarkable and viral serologies
were negative. Microscopic urine examination displayed
four red cells M/L and 123 white cells with 3% of eosi-
nophils. Urine cultures were positive for penicillin resist-
ant citrobacter koseri. Abdominal ultrasound showed
multiple cortical cysts of the left kidney, no pyelocaliceal
dilatation and the presence of multiple gallstones.
A renal biopsy was performed. Glomeruli displayed no
abnormalities. Examination of the tubulointerstitial space
revealed diffuse tubular atrophy with epithelial cell desquam-
ation and necrosis as well as the presence of numerous intra-
tubular and intracytoplasmic oxalate crystals presenting
birefringrence under polarized light (Figure 1 a, b). Chronic
interstitial nephritis characterized by an infiltration of
lymphocytes and histiocytes was also seen. Immuno-
fluoresence studies were negative. Infrared analysis of the
biopsy confirmed the presence of whewellite, a rare form
of crystallization of monohydrated calcium oxalate.
When asked again, the patient reported no history of
vitamin C supplementation or excessive oxalate intake, no
history of urinary tract stones and no relevant familial dis-
ease. During his hospital stay, no diarrhea was noted.
A complete urinary collection displayed elevated urin-
ary oxalate excretion, with a low citrate level (Table 1).
Primary hyperoxaluria was excluded as the urinary dos-
age of glycolate and l-glyceric acid were negative.A diagnosis of oxalate nephropathy with tubulointersti-
tial fibrosis secondary to enteric hyperoxaluria caused by
octretotide and multiple antibiotic therapies was made.
Hydration was undertaken and octreotide therapy was
stopped. Oral calcium and citrate supplementation were
prescribed. Creatinine levels slowly decreased and he
was discharged with a nephrologic follow up. The evolu-
tion of his condition was slowly favorable (Figure 1.c). A
new urinary collection performed 10 months after with-
drawal of octreotide therapy (Table 1) showed normal
urinary oxalate excretion.
Discussion
Hyperoxaluria leading to oxalate nephropathy is classi-
fied as primary or secondary and can manifest clinically
by acute or progressive renal failure, nephrolithiasis and
nephrocalcinosis. Primary hyperoxaluria is caused by a
genetic defect in glycoxylate metabolism. Secondary
hyperoxaluria results from varied enteric absorptive dis-
orders such as pancreatic insufficiency, inflammatory
bowel disease or jejuno-ileal bypass and also from high
consumption of oxalate-rich food [1-4]
In the present case, octreotide that was administered
for acromegaly probably had an important role in the
pathogenesis of oxalate nephropathy. This synthetic
somatostatin binds to somatotstatin-receptor subtypes 2,
3,and 5 and inhibits the release of 5-hydroxytryptamine
(5-HT) and the secretion of insulin, glucagon, secretin,
gastrin, vasoactive intestinal peptide (VIP), motilin, pan-
creatic polypeptide (PP), IGF-1 and growth hormone [5].
The most frequent side effects of octreotide are diarrhea,
abdominal discomfort and gallstone formation in rela-
tion to inhibition of pancreatic exocrine secretions. In
addition, inhibition of pancreatic secretions may cause
steatorrhea and malabsoption leading to preferential
binding of enteral calcium with fatty acids resulting in
increased amounts of free oxalate for enteric absorption.
Bile salts and malabsorbed fatty acids modify the colonic
mucosa also leading to increased oxalate absorption [6].
These two phenomena result in an increased oxalate ab-
sorption followed by enhanced urinary oxalate excretion,
and the formation of urinary calcium oxalate crystals.
A striking element in our patient’s history was his re-
cent prolonged antibiotic treatment. Indeed the colonic
flora contains Oxalobacter formigenes, a non pathogenic
gram-negative anaerobic rod of the gastrointestinal tract.
This bacterium plays a regulating role in oxalic acid ab-
sorption in the colon by using oxalate as its unique en-
ergy source. It not only degrades oxalate but also creates
a transepithelial gradient favorable to colonic secretion
of oxalate. The destruction of this organism increases
the enteral absorption of oxalate leading to an increased ex-
cretion of urinary oxalate. A direct association between
antibiotic consumption and the absence of O. formigenes in
Figure 1 a) diffuse tubular lesions with numerous oxalate crystals Hematoxylin and eosin (HE) staining; original magnification 130×. b)
diffuse tubular lesions with numerous oxalate crystals presenting birefringence under polarized light. c) Course of serum creatinine.
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hyperoxaluria on long-term antibiotic treatments have been
recorded, mostly in patients already at risk of hyperoxaluria,
such as patients suffering from pancreatic insufficiency or
inflammatory bowel disease. [7-9].
Our patient suffered from two episodes of acute kid-
ney injury shortly after the use of different antibiotics. It
is likely that an alteration in the bacterial flora caused by
the antibiotic therapy dramatically enhances oxalate en-
teric absorption leading to acute oxalate nephropathy ina patient with chronic malabsorption related to chronic
octreotide treatment, as indicated by the gall stones and
weight loss. The evolution of this condition was favor-
able following hydration and withdrawal of antibiotic
and octreotide treatments, resulting in normalization of
oxalate urinary excretion.
Conclusions
This case highlights the fact that acute kidney injury in
the context of antibiotics should evoke the differential
Table 1 Results of urinary collection performed upon hospital admission and ten months after cessation of octreotide
therapy
Parameters During hospitalization 10 months after hospitalization and stopping octreotide therapy Normal values
Fractional excretion of sodium (%) 10.1 1.07 <1
Fractional excretion of urea (%) 49.4 36.6 <35
UCa (micromol/24 hour) 2.24 1.2 2.5 to 7.5
UPh (micromol/24 hour) 5.4 19.8 13 to 42
UOx (micromole/24 hour) 1150 255 78 to 89
UGlycerate/Cr (mmol/mol) 7 <108
UGlycolate/Cr (micromol/mol) 2 <6
UCitrate/Cr (micromol/mol) 12 <457
UIsocitrate/Cr (micromol/mol) 8 <49
Plasma oxalate (micromole/L) 5 <33
U, urinary.
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and that octreotide should be considered a risk factor
for enteric hyperoxaluria.
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